Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 9;73(10):1599-1600.
doi: 10.1136/gutjnl-2024-332577.

Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus

Nicola Frericks  1 , Volker Kinast  2 , Eike Steinmann  3   4
Affiliations

Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus

Nicola Frericks et al. Gut. .
No abstract available

Keywords: CYSTIC FIBROSIS; HEPATITIS E.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
High prevalence of HEV-3 RNA in PERT correlates with an increased HEV seroprevalence in a Canadian cohort of individuals suffering from cystic fibrosis. Roughly 40% of porcine-derived PERT medications sourced from Canadian suppliers exhibited detectable levels of HEV-3 RNA. The potential contamination of PERT with infectious HEV might contribute to the increased prevalence of HEV antibodies and the chronic progression of HEV infection among cystic fibrosis patients when compared with a control group showing clinical indications of viral hepatitis. Figure created with BioRender.com. HEV, hepatitis E virus; PERT, pancreatic replacement therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization (WHO) . Hepatitis E. 2023. Available: https://www.who.int/news-room/fact-sheets/detail/hepatitis-e
    1. Rein DB, Stevens GA, Theaker J, et al. . The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012;55:988–97. 10.1002/hep.25505 - DOI - PubMed
    1. Nimgaonkar I, Ding Q, Schwartz RE, et al. . Hepatitis E virus: advances and challenges. Nat Rev Gastroenterol Hepatol 2018;15:96–110. 10.1038/nrgastro.2017.150 - DOI - PMC - PubMed
    1. Pischke S, Greer M, Hardtke S, et al. . Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. Transpl Infect Dis 2014;16:333–9. 10.1111/tid.12183 - DOI - PubMed
    1. Shah P, Lowery E, Chaparro C, et al. . Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients. J Heart Lung Transplant 2021;40:539–56. 10.1016/j.healun.2021.04.011 - DOI - PubMed

LinkOut - more resources